Everything below concerns SR9009. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-06. Numbers and descriptions here follow the published literature rather than marketing material.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
=== Altered substrate availability: lowered CO2 or increased O2 === Factors which influence this include the atmospheric abundance of the two gases, the supply of the gases to the site of fixation (i.e. in land plants: whether the stomata are open or closed), the length of the liquid phase (how far these gases have to diffuse through water in order to reach the reaction site). For example, when the stomata are closed to prevent water loss during drought: this limits the CO2 supply, while O2 production within the leaf will continue. In algae (and plants which photosynthesise underwater) gases have to diffuse significant distances through water, which results in a decrease in the availability of CO2 relative to O2. It has been predicted that the increase in ambient CO2 concentrations predicted over the next 100 years may lower the rate of photorespiration in most plants by around 50%. However, at temperatures higher than the photosynthetic thermal optimum, the increases in turnover rate are not translated into increased CO2 assimilation because of the decreased affinity of Rubisco for CO2.
== Malignant neoplasm of lip, oral cavity, and pharynx (140–149) == 140 Malignant neoplasm of lip 141 Malignant neoplasm of tongue 142 Malignant neoplasm of major salivary glands 143 Malignant neoplasm of gum 144 Malignant neoplasm of floor of mouth 145 Malignant neoplasm of other and unspecified parts of mouth 146 Malignant neoplasm of oropharynx 147 Malignant neoplasm of nasopharynx 148 Malignant neoplasm of hypopharynx 149 Malignant neoplasm of other and ill-defined sites within the lip
patent, Preparation of a Whey Protein Concentrate, combined pretreatment and ultrafiltration with water injection and cation exchange to produce a low-mineral, acid-soluble whey protein concentrate suitable for beverage formulations. The water-injection step, or diafiltration, adds water during ultrafiltration so that additional lactose, minerals, and other permeable constituents are removed, while retaining the protein. Diafiltration subsequently became an important method for manufacturing higher-protein whey protein concentrates and whey protein isolates. The New Zealand Dairy Board received a non-exclusive, royalty-free license to use the Coca-Cola process with New Zealand whey. The Dairy Board and NZDRI continued investing in whey-protein processing and product development. The work initiated for Coca-Cola generated deep expertise and provided a technological base for developing whey protein concentrates for other applications and markets. In 1982, the industry established the Whey Products Corporation to coordinate whey processing, investment, and marketing across the cooperative dairy sector. This approach enabled New Zealand to become a leading supplier of technically demanding whey-protein products during the 1980s and 1990s. The industry's centralized whey-products operations were later folded back into the Dairy Board, which merged with Kiwi Co-operative Dairies and New Zealand Dairy Group in 2001 to form Fonterra.
18 March to 28 February 1971 The 196th Light Infantry Brigade and ARVN 5th Regiment, 2nd Division launched Operation Frederick Hill to pacify the coastal areas of Quảng Tín Province. The operation results in 7,514 PAVN/VC killed and 133 captured, U.S. losses are 572 killed.
==== Government budgetary limitations ==== Instituting MS/MS screening often requires a sizable up front expenditure. When states choose to run their own programs the initial costs for equipment, training and new staff can be significant. Moreover, MS/MS gives only the screening result and not the confirmatory result. The same has to be further done by higher technologies or procedure like GC/MS, Enzyme Assays or DNA Tests. This in effect adds more cost burden and makes physicians lose precious time. To avoid at least a portion of the up front costs, some states such as Mississippi have chosen to contract with private labs for expanded screening. Others have chosen to form Regional Partnerships sharing both costs and resources. But for many states, screening has become an integrated part of the department of health which can not or will not be easily replaced. Thus the initial expenditures can be difficult for states with tight budgets to justify. Screening fees have also increased in recent years as health care costs rise and as more states add MS/MS screening to their programs. (See Report of Summation of Fees Charged for Newborn Screening, 2001–2005) Dollars spent for these programs may reduce resources available to other potentially lifesaving programs. It was recommended in 2006 that one disorder, Short Chain Acyl-coenzyme A Dehydrogenase Deficiency, or SCAD, be eliminated from screening programs, due to a "spurious association between SCAD and symptoms.
Sources: en.wikipedia.org
=== On-the-way model === Roadie’s app works by connecting drivers with senders, businesses or consumers who have items that need to be delivered. Deliveries within the app are referred to as "Gigs", which Gorlin said was inspired by live music road crews, also known as roadies. A sender creates a Gig on Roadie's web app or via its API. Drivers then review deliveries in their area on their mobile app and may choose to offer to take on individual or groups of deliveries along the same route. Gigs are then assigned to drivers by Roadie's algorithm. According to the company, this model encourages drivers to choose Gigs that align with their planned schedules and routes. Roadie calls this its "on-the-way" delivery model. The go-to-market approach taken by Roadie also differs from its competitors. Rather than launching in major cities and sequentially adding new markets city-by-city, Roadie launched nationwide from its inception. The company relies on retail and airline partners to drive volume of deliveries in individual markets, which in turn builds up a network of drivers in those areas, making it easier for small businesses and consumers to send deliveries as well. This strategy allows Roadie to reach smaller cities and towns in rural or exurban communities, traditionally difficult markets for delivery providers to serve.
=== United States === The United States Code of Federal Regulations standard for blue cheese specifies a minimum milkfat content of 50 percent, and maximum moisture of 46 percent. Optional ingredients permitted include food coloring to neutralize the yellowish tint of the cheese, benzoyl peroxide bleach, and vegetable wax for coating the rind.
== June 6, 1915 (Sunday) == Third Battle of Krithia — British general Aylmer Hunter-Weston managed to reorganize the Allied forces into an effective defense on the coast of Gallipoli and beat back the Ottoman defense, inflicting 3,000 casualties and forcing a stalemate. Second Battle of Artois — The French captured the main road leading to Neuville-Saint-Vaast, France. British carrier SS Immingham was lost in the Mediterranean Sea. Switzerland held a referendum on a war tax with most voters, over 450,000 (94 percent of electorate), in favor on implementing the one-off tax and over 27,000 against (about 6 percent). It was the first time a referendum has passed in every Swiss canton. The BHP Newcastle Steelworks opened in Newcastle, New South Wales, Australia. The London Underground extended the Bakerloo line with a new tube station at Maida Vale. The Icelandic sports club Þór Akureyri was established, and now encompasses teams for association football, basketball, handball and taekwondo.
Villhauer at Novartis started to explore N-substituted glycinyl-cyanopyrrolidines based on the fact that DPP-4 identifies N-methylglycine as an N-terminal amino acid. This group of new cyanopyrrolidines became extremely popular field of research in the following years. Some trials with dual inhibitors of DPP-4 and vasopeptidase have been represented, since vasopeptidase inhibition is believed to enhance the antidiabetic effect of DPP-4 inhibition by stimulating insulin secretion. Vasopeptidase-inhibiting motif is connected to the DPP-4 inhibitor at the N-substituent.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.